Toronto Stock Exchange Symbol: MS
EDMONTON, Nov. 14 /CNW/ - BioMS Medical Corp (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced
financial and operational results for the third quarter, ended September 30,
"During the quarter, we continued to maintain momentum towards the
commercialization of our lead drug, MBP8298, for the treatment of multiple
sclerosis," said Kevin Giese, President and CEO of BioMS Medical.
Third Quarter 2007 Highlights:
- The independent Data Safety Monitoring Board (DSMB) for MINDSET-01,
the Company's on-going phase II trial of MBP8298 for relapsing-
remitting MS, completed a safety analysis and recommended that the
trial continue as per protocol. This double blind phase of this trial
is expected to complete in the second half of 2008.
- Subsequent to the end of the quarter,
- Two posters presented at the 23rd Congress of the European
Committee for Treatment and Research in Multiple Sclerosis
(ECTRIMS) in Prague, Czech Republic, in respect of the phase
III MAESTRO-01 secondary progressive MS (SPMS) study, showed
that over 70% of the screened patients had the drug's target
HLA DR2 and/or DR4 responder genes, and that an interim
analysis showed no significant safety concerns with the drug.
An interim safety and efficacy analysis for MAESTRO-01 is
planned for mid-2008.
- The Company announced that the U.S. pivotal phase III SPMS
trial, MAESTRO-03, is on track for full enrollment in 2008, and
completed enrollment of the first 133 patients who will form
the basis of an interim analysis that is expected in 2009.
The consolidated net loss for the three months ended September 30, 2007
was $10.9 million or ($0.12) per share, compared to a consolidated net loss of
$9.2 million or ($0.14) per share for the third quarter of 2006. For the nine
months ended September 30, 2007, the consolidated net loss was $35.5 million
or ($0.43) per share compared to $26.8 million or ($0.41) per share for the
corresponding period in 2006. The increase in the loss was the result of
larger research and development expenditures and an increase in general and
Total consolidated expenses for the three months ended September 30, 2007
were $11.2 million compared to $9.6 million for the three months ended
September 30, 2006. Total consolidated expenses for the nine months ended
September 30, 2007 were $36.8 million compared with $27.8 million for the nine
months ended September 30, 2006.
Research and development expenses for the three months ended September
30, 2007 totaled $9.7 million compared with $8.1 million for the same period
in 2006. For the nine months ended September 30, 2007, research and
development expenses totaled $30.4 million compared with $22.7 million for the
same period in 2006. The increase in expenses is the result of full enrollment
in the MAESTRO-01 trial with total patient enrollment of 611 patients, full
enrollment of the MINDSET-01 trial with 218 patients, commencement of
roll-over of patients from the MAESTRO-01 trial into the open label MAESTRO-02
trial and commencement of enrollment of patients in the MAESTRO-03 trial.
General and administrative expenses totaled $1.1 million for the three
months ended September 30, 2007 compared with $1.2 million for the three
months ended September 30, 2006. For the nine months ended September 30, 2007
general and administrative expenses increased to $5.2 million compared to
$3.9 million for the nine months ended September 30, 2006. The increase in
general and administrative expenses is the result of increased public and
investor relations, increased expenses related to the public company listing
and an increase in the general business activities of the corporation.
Investment income earned on funds invested was $0.4 million for the three
months ended September 30, 2007, the same amount that was earned for the three
months ended September 30, 2006. For the nine months ended September 30, 2007,
investment income was $1.3 million compared to $0.9 million for the nine
months ended September 30, 2006. Investment income is earned from the
short-term investment of cash reserves in low-risk term deposits and
high-quality low-risk funds.
As at September 30, 2007, cash and short-term investments totaled
$49.2 million as compared to $43.1 million at December 31, 2006. As at
September 30, 2007, the Corporation had working capital of $45.9 million as
compared to $37.4 million at December 31, 2006. Management estimates that the
current working capital is sufficient for the Corporation to meet its
obligations in respect of the currently initiated clinical trials through to
the latter part of 2008.
As at November 14, 2007 there were 91,339,823 Class "A" common shares of
the Company issued and outstanding.
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and
commercialization of novel therapeutic technologies. BioMS Medical's lead
technology, MBP8298, is for the treatment of multiple sclerosis and is being
evaluated in two pivotal phase III clinical trials for secondary progressive
MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United
States. It additionally is being evaluated for relapsing remitting MS patients
in a Phase II trial in Europe entitled MINDSET-01. For further information
please visit our website at www.biomsmedical.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of BioMS Medical with respect to
its performance, business and future events. Such statements are subject to a
number of risks, uncertainties and assumptions. Actual results and events may
For further information:
For further information: Tony Hesby, Ryan Giese, Corporate
Communications, BioMS Medical Corp., (780) 413-7152, (780) 408-3040 Fax,
E-mail: firstname.lastname@example.org, Internet: www.biomsmedical.com; James Smith,
Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080 Fax, E-mail: